ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2015, Vol. 24 ›› Issue (3): 270-274.

• 论文 • 上一篇    下一篇

终末期肾病患者甲状旁腺素水平目标值的设定

  

  • 出版日期:2015-06-28 发布日期:2015-07-01

Target value of serum parathyroid hormone lever in end-stage renal disease

  • Online:2015-06-28 Published:2015-07-01

摘要:

摘要 甲状旁腺素(PTH)由甲状旁腺分泌,是慢性肾脏病骨矿物质代谢异常(CKD-MBD)重要的指标。PTH值受个体差异、饮食、采血时间及不同检测方法的影响存在变异性。终末期肾病(ESRD)患者PTH目标值的范围主要根据骨折发生率和死亡率划定,但尚无确凿证据说明PTH与死亡率的因果关系。用PTH的变化趋势而不是一次孤立的检测值来指导临床,结合其他影响因素综合理解CKD-MBD是目前的主流观点。2009年KDIGO指南制定ESRD患者的PTH目标值范围较2003年K/DOQI指南放宽,带来PTH均值呈升高趋势。规范检测方法、探索有益生存的目标值范围是今后研究的方向。

关键词: 甲状旁腺素, 终末期肾病, 慢性肾脏病矿物质与骨异常, 变异性

Abstract:

ABSTRACT Parathyroid hormone (PTH), secreted by parathyroid glands, is an important index of chronic kidney disease-mineral and bone disorder (CKD-MBD). PTH value have variability due to individual differences, diet, blood sampling time and detection methods. PTH target of End-stage Renal Disease(ESRD) is assumed by fraction risk and mortality. But with the absence of robust evidence by far, the causal relationship between PTH and outcome has not been confirmed. The popular view on reading PTH value is to consider the change trend rather than an isolated detection value to guide the clinical practice, and the comprehensive judgment of PTH value should be combined with other related factors. The range of KDIGO guideline(2009)for ESRD is larger than K/DOQI guideline(2003), which cause an increase in mean lever of PTH globaly. To detect a regular method and a proposal target of PTH still have a long way to go.

Key words: parathyroid hormone, End-stage Renal Disease, Chronic Kidney Disease –Mineral and Bone Disorder, variability